Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
The findings demonstrate the benefit of clinic-level educational interventions
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US
Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction
Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction